Premium
Autoimmune thrombocytopenia
Author(s) -
CHONG B. H.,
HO S.J.
Publication year - 2005
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/j.1538-7836.2005.01376.x
Subject(s) - medicine , splenectomy , platelet , refractory (planetary science) , autoimmune thrombocytopenia , thrombocytopenic purpura , antibody , immunology , gastroenterology , spleen , physics , astrobiology
Summary. Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder in which platelets coated with mainly antibodies against platelet GPIIb/IIIa and GPIb/IX are destroyed in the spleen. Recent evidence suggests that platelets are also destroyed by cytotoxic T cells. The diagnosis is made by exclusion for other causes of thrombocytopenia. As routine blood counts are becoming more available, many mild cases of ITP (platelets >30 × 10 9 L −1 ) are being diagnosed and they usually do not require treatment. In patients with platelet counts persistently <30 × 10 9 L −1 , treatment with cortisteroids, and/or intravenous immunoglobulin (IVIG) or anti‐D may be required. The primary goal of treatment is to maintain the platelet count at a safe level with minimal side effects. After 3–6 months, if spontaneous remission has not occurred and if the side effects are significant, splenectomy is recommended. This is the single most effective treatment of ITP. The refractory patients who fails splenectomy and subsequently first‐ and second‐line therapies, is a management dilemma. Therapeutic options are limited, available treatments potentially toxic and the chances of sustained response low. Observation with no active treatment is a reasonable option. With the increased availability of the thrombopoietic agents in the future, there may be a good prospect of keeping the platelet counts of these refractory patients at a safe long‐term level with one of these drugs.